Pivotal phase IIb trial of brivudine in patients with advanced pancreatic cancer.

Trial Profile

Pivotal phase IIb trial of brivudine in patients with advanced pancreatic cancer.

Planning
Phase of Trial: Phase II

Latest Information Update: 08 Feb 2016

At a glance

  • Drugs Brivudine (Primary)
  • Indications Pancreatic cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors RESprotect
  • Most Recent Events

    • 08 Feb 2016 According to a RedHill Biopharma media release, brivudine has received Orphan Drug Designation for the adjunct treatment of pancreatic cancer by the US FDA and the EMA.
    • 30 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top